litlas
Log inCreate account

Neil H. Bander

Active 1985–2024

85
Papers
20,854
Citations
70
h-index
84
i10-index

Citations

Citations per year for Neil H. Bander1986: 2 citations1987: 1 citations1988: 15 citations1989: 32 citations1990: 19 citations1991: 24 citations1992: 13 citations1993: 13 citations1994: 29 citations1995: 42 citations1996: 35 citations1997: 61 citations1998: 65 citations1999: 88 citations2000: 91 citations2001: 91 citations2002: 123 citations2003: 160 citations2004: 145 citations2005: 187 citations2006: 129 citations2007: 134 citations2008: 148 citations2009: 138 citations2010: 151 citations2011: 176 citations2012: 226 citations2013: 236 citations2014: 231 citations2015: 249 citations2016: 310 citations2017: 243 citations2018: 250 citations2019: 550 citations2020: 549 citations2021: 594 citations2022: 370 citations2023: 224 citations2024: 372 citations2025: 149 citations2026: 1 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,415 citing papers, 34.1% of this breakdownChina: 659 citing papers, 9.3% of this breakdownGermany: 513 citing papers, 7.2% of this breakdownUnited Kingdom: 340 citing papers, 4.8% of this breakdownItaly: 255 citing papers, 3.6% of this breakdownCanada: 238 citing papers, 3.4% of this breakdownAustralia: 219 citing papers, 3.1% of this breakdownFrance: 217 citing papers, 3.1% of this breakdownNetherlands: 217 citing papers, 3.1% of this breakdownJapan: 200 citing papers, 2.8% of this breakdownIndia: 161 citing papers, 2.3% of this breakdownSwitzerland: 151 citing papers, 2.1% of this breakdown
0%34.1%Other 21.1%

Institutions

Fields

  • Medicine56%
  • Biochemistry, Genetics and Molecular Biology25.7%
  • Materials Science8.3%
  • Immunology and Microbiology4.2%
  • Engineering3.4%
  • Neuroscience0.6%
  • Other1.8%

Topics

  • Radiopharmaceutical Chemistry and Applications7.1%
  • Prostate Cancer Treatment and Research6.7%
  • Renal cell carcinoma treatment4.1%
  • Nanoparticle-Based Drug Delivery3.3%
  • RNA Interference and Gene Delivery2.7%
  • Prostate Cancer Diagnosis and Treatment2.2%
  • Other73.9%

Coauthors

All papers

Open in search
  1. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Authors: Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali, Elizaveta A. Andrianova, Jason Auer, Tarikh Campbell, David De Witt, Michael Figa, Maria J. Figueiredo, Allen Horhota, Susan C. Low, Kevin McDonnell, Erick Peeke, Beadle Retnarajan, Abhimanyu Sabnis, Edward F. Schnipper, Jeffrey Song, Young Ho Song, Jason M. Summa, Douglas Tompsett, Greg Troiano, Tina Van Geen Hoven, Jim Wright, Patricia LoRusso, Philip W. Kantoff, Neil H. Bander, Christopher Sweeney, Omid C. Farokhzad, Róbert Langer, Stephen E. Zale - Science Translational Medicine 2012 cited by 1,119

  2. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

    Authors: Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin‐Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner - JCI Insight 2023 cited by 82

  3. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

    Authors: Scott T. Tagawa, Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar, Shankar Vallabhajosula, Sandra Huicochea Castellanos, Jones T. Nauseef, Cora N. Sternberg, Ana M. Molina, Karla V. Ballman, David M. Nanus, Joseph R. Osborne, Neil H. Bander - Journal of Clinical Oncology 2023 cited by 67

  4. Mutations of the VHL tumour suppressor gene in renal carcinoma

    Authors: James R. Gnarra, Kálmán Tory, Y Weng, Laura S. Schmidt, Ming Wei, Hu Li, Farida Latif, S. Liu, F. Chen, F M Duh, Irina A. Lubensky, Delin Duan, Charles Florence, Rudy Pozzatti, McClellan M. Walther, Neil H. Bander, H. Barton Grossman, Hiltrud Brauch, S. Pomer, James D. Brooks, William B. Isaacs, Michael I. Lerman, Berton Zbar, W. Marston Linehan - Nature Genetics 1994 cited by 1,741

  5. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

    Authors: Dimple Chakravarty, Andrea Sboner, Sujit S. Nair, Ευγενία Γιαννοπούλου, Ruohan Li, Sven Hennig, Juan Miguel Mosquera, Jonathan Pauwels, Kyung Park, Myriam Kossaï, Theresa Y. MacDonald, Jacqueline Fontugne, Nicholas Erho, Ismael A. Vergara, Mercedeh Ghadessi, Elai Davicioni, Robert B. Jenkins, Nallasivam Palanisamy, Zhengming Chen, Shinichi Nakagawa, Tetsuro Hirose, Neil H. Bander, Himisha Beltran, Archa H. Fox, Olivier Elemento, Mark A. Rubin - Nature Communications 2014 cited by 630

  6. Tumor Therapy with Targeted Atomic Nanogenerators

    Authors: Michael R. McDevitt, Dangshe Ma, Lawrence Lai, Jim Simón, Paul E. Borchardt, R. Keith Frank, Karen Wu, V Pellegrini, Michael Curcio, Matthias Miederer, Neil H. Bander, David A. Scheinberg - Science 2001 cited by 504

  7. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

    Authors: Sam S. Chang, Victor E. Reuter, W. D. W. Heston, Neil H. Bander, Lana S. Grauer, Paul B. Gaudin - 1999 cited by 814

  8. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

    Authors: Scott T. Tagawa, Matthew I. Milowsky, Michael J. Morris, Shankar Vallabhajosula, Paul J. Christos, Naveed Akhtar, Joseph R. Osborne, Stanley J. Goldsmith, Steven M. Larson, Neeta Pandit Taskar, Howard I. Scher, Neil H. Bander, David M. Nanus - Clinical Cancer Research 2013 cited by 426

  9. Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

    Authors: He Liu, A K Rajasekaran, P. Moy, Yan Xia, Sae Kim, Vincent Navarro, R Rahmati, Neil H. Bander - 1998 cited by 448

  10. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

    Authors: Neil H. Bander, Matthew I. Milowsky, David M. Nanus, Lale Kostakoğlu, Shankar Vallabhajosula, Stanley J. Goldsmith - Journal of Clinical Oncology 2005 cited by 508

  11. Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer

    Authors: Scott T. Tagawa, Shankar Vallabhajosula, Paul J. Christos, Yuliya Jhanwar, Jaspreet S. Batra, Linda Lam, Joseph R. Osborne, Himisha Beltran, Ana M. Molina, Stanley J. Goldsmith, Neil H. Bander, David M. Nanus - Cancer 2019 cited by 133

  12. Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Neil H. Bander, David M. Nanus - New England Journal of Medicine 1996 cited by 2,248

  13. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

    Authors: He Liu, P. Moy, Sae Kim, Yan Xia, Ayyappan K. Rajasekaran, Vincent Navarro, Beatrice Knudsen, Neil H. Bander - 1997 cited by 531

  14. Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

    Authors: Medha S. Darshan, Matthew S. Loftus, Maria Thadani‐Mulero, Benjamin Levy, Daniel Escuín, Xi Kathy Zhou, Ada Gjyrezi, Chantal Chanel‐Vos, Ruoqian Shen, Scott T. Tagawa, Neil H. Bander, David M. Nanus, Paraskevi Giannakakou - Cancer Research 2011 cited by 427

  15. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

    Authors: Jason P. Gleghorn, Erica D. Pratt, Denise Denning, He Liu, Neil H. Bander, Scott T. Tagawa, David M. Nanus, Paraskevi Giannakakou, Brian J. Kirby - Lab on a Chip 2009 cited by 390

  16. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

    Authors: Michael J. Evans, Peter Smith‐Jones, John Wongvipat, Vincent Navarro, Sae Kim, Neil H. Bander, Steven M. Larson, Charles L. Sawyers - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 317

  17. Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

    Authors: Jaspreet S. Batra, Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos, Shankar Vallabhajosula, Yuliya Jhanwar, Ana M. Molina, David M. Nanus, Joseph R. Osborne, Neil H. Bander, Scott T. Tagawa - Urologic Oncology Seminars and Original Investigations 2020 cited by 48

  18. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

    Authors: Jason P. Holland, Vadim Divilov, Neil H. Bander, Peter Smith‐Jones, Steven M. Larson, Jason S. Lewis - Journal of Nuclear Medicine 2010 cited by 409

  19. Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

    Authors: Neil H. Bander, Edouard J. Trabulsi, Lale Kostakoğlu, Daniel Yao, Shankar Vallabhajosula, Peter Smith‐Jones, Maureen A. Joyce, Matthew I. Milowsky, David M. Nanus, Stanley J. Goldsmith - The Journal of Urology 2003 cited by 260

  20. A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen

    Authors: Sigrid A. Rajasekaran, Anilkumar Gopalakrishnapillai, Eri Oshima, James U. Bowie, He Liu, Warren D.W. Heston, Neil H. Bander, Ayyappan K. Rajasekaran - Molecular Biology of the Cell 2003 cited by 221

  21. Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers

    Authors: Alla Gabriella Wernicke, Sonal Varma, Eleni A. Greenwood, Paul J. Christos, K. Chao, He Liu, Neil H. Bander, Sandra J. Shin - Apmis 2013 cited by 126

  22. Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen

    Authors: Michael Gong, Jean‐Baptiste Latouche, Anja Krause, Warren D.W. Heston, Neil H. Bander, Michel Sadelain - Neoplasia 1999 cited by 241

  23. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

    Authors: Michael C. Haffner, Irmgard Kronberger, Jeffrey S. Ross, Christine E. Sheehan, Matthias Zitt, Gilbert Mühlmann, Dietmar Öfner, Bettina Zelger, Christian Ensinger, Ximing J. Yang, Stephan Geley, Raimund Margreiter, Neil H. Bander - Human Pathology 2009 cited by 233

  24. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

    Authors: Neeta Pandit‐Taskar, Joseph A. O’Donoghue, Jeremy C. Durack, Serge K. Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A. Lefkowitz, Jorge A. Carrasquillo, Danny F. Martinez, Alex Mak Fung, Stephen B. Solomon, Mithat Gönen, Glenn Heller, Massimo Loda, David M. Nanus, Scott T. Tagawa, Jarett L. Feldman, Joseph R. Osborne, Jason S. Lewis, Victor E. Reuter, Wolfgang Weber, Neil H. Bander, Howard I. Scher, Steven M. Larson, Michael J. Morris - Clinical Cancer Research 2015 cited by 204